ASH 2020 | Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA discusses the preliminary findings of a Phase I study (NCT03269136) of PF-3135, a bispecific monoclonal antibody, in relapsed/refractory multiple myeloma (MM). PF-3135 targets BCMA, a highly expressed myeloma cell antigen, and CD3, enabling T cell cytotoxic targeting of myeloma cells. Subcutaneous (SC) dose escalation was carried out in 18 patients: no dose-limiting toxicities were observed and the maximum tolerated dose not reached. Adverse events were generally tolerable; the most common was cytokine release syndrome. The overall response rate was 75% when observing the top two dose levels only. SC dose escalation is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
